Drisapersen
- Generic Name
- Drisapersen
- Drug Type
- Small Molecule
- CAS Number
- 1251830-50-8
- Unique Ingredient Identifier
- 73D586DAMF
Extension Study of Drisapersen in DMD Subjects
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- BioMarin Pharmaceutical
- Registration Number
- NCT02636686
- Locations
- ๐ง๐ช
Universitair Ziekenhuis Gent, Afdeling Neurologie, Gent, Belgium
๐ง๐ชQueen Fabiola Children's University Hospital, Brussels, Belgium
๐ฏ๐ตNational Hospital Organization, Saitama, Japan
A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 12
- Registration Number
- NCT01910649
Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01890798
A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 53
- Registration Number
- NCT01803412
- Locations
- ๐บ๐ธ
UC Davis Medical Center, Sacramento, California, United States
๐บ๐ธUniversity of Iowa, Iowa City, Iowa, United States
๐บ๐ธKennedy Krieger Institute, Baltimore, Maryland, United States
Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 233
- Registration Number
- NCT01480245
- Locations
- ๐ฌ๐ง
GSK Investigational Site, Newcastle-upon-Tyne, United Kingdom
Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2014-08-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 53
- Registration Number
- NCT01153932
- Locations
- ๐ฌ๐ง
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath